Uterine Cancer Mortality on the Rise, but Research Remains Underfunded
Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.
Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.
Researchers sought to determine whether survivors of gynecologic cancers had a higher risk of sexual dysfunction, compared with cancer-free women, and the risk factors for sexual dysfunction.
A report from the American Cancer Society reveals trends in cancer incidence and mortality over time and includes projections for 2023.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
The highest rate of non-concordant care was seen in patients with cervical cancer.
About 63% of patients were diagnosed with stage II or higher disease.
The approval was based on data from the phase 2 innovaTV 204 trial that evaluated Tivdak as monotherapy in 101 adult females with recurrent or metastatic cervical cancer.
Researchers analyzed recent trends in cervical cancer incidence and mortality and made predictions for the next 15 years.
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.